Hem › Icke-småcellig lungcancer › District of Columbia › Washington
Kliniska studier för Icke-småcellig lungcancer i Washington, DC
55 studier för Icke-småcellig lungcancer söker deltagare vid platser i och runt Washington (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekryterarFas 3
- Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
- MedStar Georgetown University Hospital, Washington D.C.
- MedStar Washington Hospital Center, Washington D.C.
- och 1 fler
Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
RekryterarObservationsstudie
- National Institutes of Health Clinical Center, Bethesda · 7 mi bort
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
RekryterarFas 2
- Local Institution - 0183, Washington D.C.
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
RekryterarFas 3
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
A Study of PHN-012 in Patients With Advanced Solid Tumors
RekryterarFas 1
- PHN-012-001 Site, Washington D.C.
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
RekryterarFas 2
- Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital, Washington D.C.
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
RekryterarObservationsstudie
- National Institutes of Health Clinical Center, Bethesda · 7 mi bort
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
RekryterarFas 3
- Maryland Oncology Hematology, P.A., Silver Spring · 7 mi bort
- Maryland Oncology Hematology, P.A., Bethesda · 7 mi bort
- Maryland Oncology Hematology, P.A, Largo · 11 mi bort
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RekryterarFas 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi bort
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RekryterarFas 3
- Research Site, Silver Spring · 7 mi bort
- Research Site, Bethesda · 7 mi bort
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RekryterarFas 3
- Maryland Oncology Hematology, P.A., Silver Spring · 7 mi bort
- Maryland Oncology Hematology, P.A., Bethesda · 7 mi bort
- Maryland Oncology Hematology, P.A., Largo · 11 mi bort
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
RekryterarFas 2
- MedStar Georgetown University Hospital, Washington D.C.
- Washington DC VA Medical Center, Washington D.C.
- Maryland Oncology Hematology P A, Silver Spring · 7 mi bort
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
RekryterarFas 2
- Georgetown University, Washington D.C.
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RekryterarFas 3
- Washington DC Veterans Affairs Medical Center, Washington D.C.
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
RekryterarFas 2
- MedStar Georgetown University Hospital, Washington D.C.
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RekryterarFas 3
- Sibley Memorial Hospital, Washington D.C.
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
RekryterarFas 1
- National Institutes of Health Clinical Center, Bethesda · 7 mi bort
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
RekryterarFas 2/3
- MedStar Georgetown-MedStar Georgetown Transplant Institute University Hospital (MGUH), Washington D.C.
- MEDSTAR Washington Hospital Center (MedStar Health Research Institute), Washington D.C.
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RekryterarFas 1
- Georgetown University Medical Center, Washington D.C.
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
RekryterarFas 3
- Research Site, Bethesda · 7 mi bort
- Research Site, Bethesda · 7 mi bort
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
RekryterarFas 3
- George Washington University Cancer Center, Washington D.C.
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
RekryterarFas 1/2
- Georgetown University Lombardi Cancer Center, Washington D.C.
- Sibley Memorial Hospital, Washington D.C.
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
RekryterarFas 2/3
- Local Institution - 007-5476, Washington D.C.
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
RekryterarFas 2
- MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center), Washington D.C.
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RekryterarFas 3
- Sibley Memorial Hospital, Washington D.C.
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RekryterarFas 3
- Walter Reed National Military Medical Center, Bethesda · 7 mi bort
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
RekryterarFas 3
- Washington Hospital Center ( Site 0037), Washington D.C.
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
RekryterarFas 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi bort
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
RekryterarFas 3
- Research Site, Bethesda · 7 mi bort
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
RekryterarFas 2
- MedStar Georgetown University Hospital, Washington D.C.
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
RekryterarFas 1
- Sibley Memorial Hospital, Washington D.C.
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
RekryterarFas 3
- Sibley Memorial Hospital, Washington D.C.
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RekryterarFas 1/2
- National Institutes of Health, Bethesda · 7 mi bort
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
RekryterarFas 1/2
- Georgetown University - Lombardi Comprehensive Cancer Center, Washington D.C.
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
RekryterarFas 1/2
- Georgetown University Medical Center, Washington D.C.
Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features
RekryterarFas 2
- Lombardi Comprehensive Cancer Center, Georgetown University, Washington D.C.
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
RekryterarFas 1/2
- Georgetown University, Washington D.C.
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
RekryterarFas 1
- Maryland Oncology Hematology, Calverton · 12 mi bort
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
RekryterarFas 1/2
- Georgetown University Medical Center, Washington D.C.
Gilteritinib for the Treatment of ALK NSCLC
RekryterarFas 1
- Georgetown University, Washington D.C.
Study of XB010 in Subjects With Solid Tumors
RekryterarFas 1
- Georgetown University Medical Center, Washington D.C.
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RekryterarFas 2
- Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
- Kaiser Permanente - Largo Medical Center, Largo · 11 mi bort
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
RekryterarFas 2
- USA11-0, Bethesda · 7 mi bort
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
RekryterarFas 3
- Georgetown University Medical Cener (GUMC), Washington D.C.
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RekryterarFas 3
- Research Site, Washington D.C.
- Research Site, Bethesda · 7 mi bort
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RekryterarFas 2/3
- Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
- Kaiser Permanente - Largo Medical Center, Largo · 11 mi bort
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RekryterarFas 2
- Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
- Kaiser Permanente - Largo Medical Center, Largo · 11 mi bort
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RekryterarFas 1/2
- Sibley Memorial Hospital, Washington D.C.
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
RekryterarFas 2
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
- Medstar Washington Hospital Center, Washington D.C.
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RekryterarFas 1
- National Cancer Institute, Bethesda · 7 mi bort
Repositioning Immunotherapy in VetArans With Lung Cancer
RekryterarFas 2
- VA Central Office, Washington, DC, Washington D.C.
GEMINI-NSCLC: NSCLC Biomarker Study
RekryterarObservationsstudie
- The Center for Cancer and Blood Disorder, Bethesda · 7 mi bort
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
RekryterarFas 1/2
- The George Washington University Cancer Center (site 212), Washington D.C.
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekryterarObservationsstudie
- Massive Bio SYNERGY-AI site, Silver Spring · 7 mi bort
- Massive Bio SYNERGY-AI site, Bethesda · 7 mi bort
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
RekryterarFas 1/2
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
Icke-småcellig lungcancer-studier i andra städer
- Houston, TX145 studier
- New York City, NY121 studier
- Arlington, VA104 studier
- Nashville, TN97 studier
- Boston, MA90 studier
- Los Angeles, CA87 studier
- St. Louis, MO73 studier
- Chicago, IL61 studier
- Baltimore, MD60 studier
- San Antonio, TX59 studier
- Columbus, OH57 studier
- Seattle, WA53 studier
Andra studier i Washington
- Cancer (alla typer)58 studier
- Bröstcancer46 studier
- Metastaserande cancer43 studier
- Lungcancer41 studier
- Prostatacancer38 studier
- Övervikt33 studier
- Kolorektal cancer29 studier
- Hjärt-kärlsjukdom28 studier
- Blåscancer26 studier
- Akut myeloid leukemi24 studier
- Äggstockscancer23 studier
- Lymfom23 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.